Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind randomized study of Tobestomig + nab-paclitaxel versus pembrolizumab + nab-paclitaxel in PD-L1-positive advanced triple-negative breast cancer
MOH_2023-05-22_012665Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Tobestomig + nab-paclitaxel with pembrolizumab + nab-paclitaxel (2 arms). Planned start Apr 2023; status: not yet recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2023-05-22_012665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-22_012665.